ANAGENICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.007 AUD | 0.00% |
|
-22.22% | -63.16% |
| May. 24 | Anagenics Signs Midkine Antibody Licencing Deal with Roquefort Therapeutics | MT |
| Mar. 08 | Anagenics Appoints CEO | MT |
| Sales 2022 | 9.23M 6.13M | Sales 2023 | 9.11M 6.05M | Capitalization | 6.22M 4.13M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -1.99M | Net income 2023 | -2M -1.33M | EV / Sales 2022 | 0.39 x |
| Net cash position 2022 | 1.53M 1.01M | Net cash position 2023 | 1.91M 1.27M | EV / Sales 2023 | 0.47 x |
| P/E ratio 2022 |
-1.32
x | P/E ratio 2023 |
-1.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.72% |
More Fundamentals
* Assessed data
More news
| 1 week | -22.22% | ||
| 1 month | -22.22% | ||
| 3 months | -41.67% | ||
| 6 months | -63.16% | ||
| Current year | -63.16% |
1 week
0.01
0.01
1 month
0.010.02
Current year
0.010.02
1 year
0.010.03
3 years
0.010.07
5 years
0.010.49
10 years
0.010.88
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Dudek
DFI | Director of Finance/CFO | - | 19-12-31 |
Dominic Burg
COO | Chief Operating Officer | - | 16-02-29 |
Scott Greasley
BRD | Director/Board Member | - | 22-07-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sandy Beard
CHM | Chairman | 58 | 22-02-14 |
Karen Matthews
CEO | Chief Executive Officer | - | 23-02-13 |
| Director/Board Member | - | 21-11-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-02 | 0.007 | 0.00% | 5 000 |
| 24-05-31 | 0.007 | 0.00% | 22,000 |
| 24-05-29 | 0.007 | -12.50% | 950,000 |
| 24-05-28 | 0.008 | -11.11% | 65,000 |
| 24-05-27 | 0.009 | 0.00% | 2,400,269 |
Delayed Quote Australian S.E., June 02, 2024 at 10:25 pm EDT
More quotes
Anagenics Limited is an Australia-based health and beauty-tech company. The Company offers a range of clinically validated anti-ageing and wellness products developed in-house or sourced from premium international brands. The Company, through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures and markets anti-aging products globally, with its FGF5 inhibitor hair health and hair growth products sold worldwide. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju and Lexilis brands, is sold in Japan, the United States of America and Australia. The Companyâs subsidiary is BLC Cosmetics Pty Limited, which is the distributor of international and local skin care and wellbeing brands.
Sector
Personal Products
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -63.16% | 2.14M | |
| +12.28% | 388B | |
| +13.34% | 136B | |
| +16.62% | 76.27B | |
| -11.37% | 65.56B | |
| -15.65% | 44.23B | |
| -10.36% | 36.96B | |
| +6.12% | 35.04B | |
| +9.24% | 18.02B | |
| +15.64% | 15.57B |
- Stock Market
- Equities
- AN1 Stock
